SCHEMBL4540366

SCHEMBL4540366

CCCc1nc2c(N)nc3ccccc3c2n1CCC(N)=O

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 20/20 0.67
TLR8 Q9NR97 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5616926 0.99 TLR7 (0.65) TLR7TLR8
SCHEMBL5617073 0.94 TLR7 (0.67) TLR7TLR8
SCHEMBL5616933 0.94 TLR7 (0.69) TLR7TLR8
SCHEMBL5616967 0.93 TLR7 (0.67) TLR7TLR8
SCHEMBL5617065 0.89 TLR7 (0.69) TLR7TLR8
SCHEMBL5617135 0.88 TLR7 (0.63) TLR7TLR8
SCHEMBL5616930 0.88 TLR7 (0.77) TLR7TLR8
SCHEMBL5616968 0.88 TLR7 (0.63) TLR7TLR8
SCHEMBL4155419 0.87 TLR7 (0.62) TLR7TLR8
SCHEMBL4139104 0.87 TLR7 (0.66) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10071156-B2 Aqueous gel formulations containing immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-09-11 US claimed
US-20160101173-A1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2016-04-14 US claimed
EP-1844201-A2 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-17 EP claimed
WO-2006084251-A2 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE REPONSE MODIFIERS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-10 WO claimed
US-10071156-B2 Aqueous gel formulations containing immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-09-11 US disclosed
EP-1844201-B1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2016-08-24 EP disclosed
US-20160101173-A1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2016-04-14 US disclosed
US-9248127-B2 Aqueous gel formulations containing immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-02-02 US disclosed
US-20090163532-A1 Aqueous Gel Formulations Containing Immune Response Modifiers COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-06-25 US disclosed
EP-1844201-A2 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-17 EP disclosed
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2007-09-20 US disclosed
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2007-09-20 US disclosed
WO-2006084251-A2 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE REPONSE MODIFIERS COLEY PHARMACEUTICAL GROUP, INC. (US) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10071156-B2 Aqueous gel formulations containing immune response modifiers IFNG, ICOS, IL4 TLR7 28/4885TLR8 94/4885
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES IL2, IL4, IFNG TLR7 123/4885TLR8 150/4885
US-20090163532-A1 Aqueous Gel Formulations Containing Immune Response Modifiers IFNG, ICOS, IL4 TLR7 28/4885TLR8 94/4885
US-20160101173-A1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS IFNG, ICOS, IL4 TLR7 28/4885TLR8 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.